Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: Product/Service

Citi Appointed as Depositary Bank for Valneva SE's ADR Programme


Citi, acting through Citibank N.A., has been appointed by Valneva SE ("Valneva"), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, to act as depositary bank for its American Depositary Receipt ("ADR") programme.

Valneva's American Depositary Shares ("ADS") trade on the Nasdaq Global Select Market under the symbol "VALN". Each ADS represents two ordinary shares of the company. Valneva's underlying ordinary shares are listed and trade on Euronext Paris under the symbol "VLA".

David Lawrence, Acting CFO of Valneva, said: "We are pleased to be working with Citi as part of our team supporting our newly acquired Nasdaq listing."

Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: "We look forward to supporting Valneva's ADR programme and expanding the company's investor outreach through the expertise of our Investor Relations Advisory team and the breadth of our global equity distribution network."

For more information on Citi's Depositary Receipt Services, visit www.citi.com/dr

About Valneva

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Additional information may be found at www.valneva.com

About Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi


These press releases may also interest you

at 16:35
DermTech, Inc. (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged TD Cowen to conduct a process exploring...

at 16:33
A bill named in memory of four-year-old Ana Lucía "Lulu" Haynes, who passed away from sepsis in 2014, has been reintroduced in the House of Representatives. It arrives ahead of next week's Pediatric Sepsis Week observance, which provides an annual...

at 16:30
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it will be presenting promising new preclinical data from its platform built (or optimized) to discover...

at 16:30
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the "MCTO"), by its principal regulator, the Ontario Securities Commission (the...

at 16:30
Evolent Health, Inc. , a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial...

at 16:30
Canopy Growth Corporation ("Canopy Growth" or the "Company") announced today that in connection with the creation of the non-voting and non-participating exchangeable shares in the capital of Canopy Growth (the "Exchangeable Shares"), on...



News published on and distributed by: